Cargando…
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
Multiple myeloma (MM) is a hematological cancer causing from accumulated abnormal plasma cells. STAT3 overexpression in MM appears to be mediated by a variety of factors, and it may be associated with an adverse prognosis and play a role in microenvironment-dependent treatment resistance. Unfortunat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064077/ https://www.ncbi.nlm.nih.gov/pubmed/35503759 http://dx.doi.org/10.1371/journal.pone.0265958 |
_version_ | 1784699290114850816 |
---|---|
author | Heo, Sook-Kyoung Noh, Eui-Kyu Seo, Hye Jin Lee, Yoo Jin Koh, SuJin Min, Young Joo Choi, Yunsuk Jo, Jae-Cheol |
author_facet | Heo, Sook-Kyoung Noh, Eui-Kyu Seo, Hye Jin Lee, Yoo Jin Koh, SuJin Min, Young Joo Choi, Yunsuk Jo, Jae-Cheol |
author_sort | Heo, Sook-Kyoung |
collection | PubMed |
description | Multiple myeloma (MM) is a hematological cancer causing from accumulated abnormal plasma cells. STAT3 overexpression in MM appears to be mediated by a variety of factors, and it may be associated with an adverse prognosis and play a role in microenvironment-dependent treatment resistance. Unfortunately, MM remains an incurable disease, as relapse is very common. Therefore, there is urgent need to develop new treatment options for MM. Radotinib is a novel anti-cancer drug, currently approved in South Korea for the treatment of chronic myeloid leukemia patients. It is an oral, multitargeted inhibitor of receptor tyrosine kinases, including BCR-ABL, c-KIT, PDGFR, and Src family kinases. However, little is known about the effects of radotinib on multiple myeloma cells. However, little is known about the effects of radotinib on multiple myeloma cells. But even tinip almost not known about the impact of multiple myeloma cells. Moreover, nothing is known about how it affects STAT3 and JAK2. In this study, we analyzed the effect of radotinib on multiple myeloma cells. Herein, Moreover, nothing is known about how it. Moreover, not all is known about how the affects STAT3 and JAK2. We investigated the effect of radotinib on the STAT3 signaling pathway in MM cells, including several MM cell lines and mouse models. So we investigated the effect of radotinib on MM cells, including several MM cell lines and mouse models. Interestingly, radotinib induced apoptosis, and inhibited cell proliferation in MM cells including RPMI-8226, MM.1S, U266B1, and IM-9 cells. Moreover, radotinib treatment significantly increased the number Annexin V-positive cells and G0/G1-phase cells. In addition, radotinib treatment in various MM cells strongly suppressed the activity and expression of STAT3 and JAK2 proteins. We also observed that diverse proteins related to the STAT3 signaling pathway, including c-Myc, Bcl-xL, Mcl-1, cyclin D1 and cyclin D3, were powerfully inhibited by radotinib treatment in MM cells. Furthermore, radotinib significantly suppressed MM cell growth in a xenograft animal model using IM-9 cells. In conclusion, radotinib may play an important role as a candidate agent for MM treatment. |
format | Online Article Text |
id | pubmed-9064077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90640772022-05-04 Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling Heo, Sook-Kyoung Noh, Eui-Kyu Seo, Hye Jin Lee, Yoo Jin Koh, SuJin Min, Young Joo Choi, Yunsuk Jo, Jae-Cheol PLoS One Research Article Multiple myeloma (MM) is a hematological cancer causing from accumulated abnormal plasma cells. STAT3 overexpression in MM appears to be mediated by a variety of factors, and it may be associated with an adverse prognosis and play a role in microenvironment-dependent treatment resistance. Unfortunately, MM remains an incurable disease, as relapse is very common. Therefore, there is urgent need to develop new treatment options for MM. Radotinib is a novel anti-cancer drug, currently approved in South Korea for the treatment of chronic myeloid leukemia patients. It is an oral, multitargeted inhibitor of receptor tyrosine kinases, including BCR-ABL, c-KIT, PDGFR, and Src family kinases. However, little is known about the effects of radotinib on multiple myeloma cells. However, little is known about the effects of radotinib on multiple myeloma cells. But even tinip almost not known about the impact of multiple myeloma cells. Moreover, nothing is known about how it affects STAT3 and JAK2. In this study, we analyzed the effect of radotinib on multiple myeloma cells. Herein, Moreover, nothing is known about how it. Moreover, not all is known about how the affects STAT3 and JAK2. We investigated the effect of radotinib on the STAT3 signaling pathway in MM cells, including several MM cell lines and mouse models. So we investigated the effect of radotinib on MM cells, including several MM cell lines and mouse models. Interestingly, radotinib induced apoptosis, and inhibited cell proliferation in MM cells including RPMI-8226, MM.1S, U266B1, and IM-9 cells. Moreover, radotinib treatment significantly increased the number Annexin V-positive cells and G0/G1-phase cells. In addition, radotinib treatment in various MM cells strongly suppressed the activity and expression of STAT3 and JAK2 proteins. We also observed that diverse proteins related to the STAT3 signaling pathway, including c-Myc, Bcl-xL, Mcl-1, cyclin D1 and cyclin D3, were powerfully inhibited by radotinib treatment in MM cells. Furthermore, radotinib significantly suppressed MM cell growth in a xenograft animal model using IM-9 cells. In conclusion, radotinib may play an important role as a candidate agent for MM treatment. Public Library of Science 2022-05-03 /pmc/articles/PMC9064077/ /pubmed/35503759 http://dx.doi.org/10.1371/journal.pone.0265958 Text en © 2022 Heo et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Heo, Sook-Kyoung Noh, Eui-Kyu Seo, Hye Jin Lee, Yoo Jin Koh, SuJin Min, Young Joo Choi, Yunsuk Jo, Jae-Cheol Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title | Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title_full | Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title_fullStr | Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title_full_unstemmed | Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title_short | Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling |
title_sort | radotinib inhibits multiple myeloma cell proliferation via suppression of stat3 signaling |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064077/ https://www.ncbi.nlm.nih.gov/pubmed/35503759 http://dx.doi.org/10.1371/journal.pone.0265958 |
work_keys_str_mv | AT heosookkyoung radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT noheuikyu radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT seohyejin radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT leeyoojin radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT kohsujin radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT minyoungjoo radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT choiyunsuk radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling AT jojaecheol radotinibinhibitsmultiplemyelomacellproliferationviasuppressionofstat3signaling |